Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Clonazepam

Preparation Calculator

USE IF: Seizure disorders (maintenance), panic disorder, and selected anxiety disorders with clear indication and follow-up plan.

AVOID IF: Severe respiratory depression, acute intoxication with CNS depressants, and high misuse risk without monitoring and safeguards.

Clonazepam

Benzodiazepine (anticonvulsant / anxiolytic)

AdultPediatricNeurologyPsychiatryBenzodiazepineWardOutpatientHigh-yield

Indication

Seizures (maintenance) · Panic disorder · Anxiety (selected cases)

At a glance

INDICATIONS (CORE USE)

- Seizure disorders (maintenance) - Panic disorder

ADULT DOSE (STANDARD)

Start low (e.g., 0.25–0.5 mg BID); titrate gradually by response and tolerance

MAX DOSE

Variable; often up to ~4 mg/day depending on indication and response

Route

PO

PEDIATRIC DOSE

Specialist / protocol-based

Do not miss

Must-not-miss safety points

Major warning

- CNS and respiratory depression (especially with opioids / alcohol) - Dependence and tolerance with chronic use - Abrupt discontinuation → withdrawal (anxiety, agitation, seizures) - Sedation → falls, impaired cognition

Indications

USE IF: Seizure disorders (maintenance), panic disorder, selected anxiety disorders. AVOID IF: Severe respiratory depression, acute intoxication with CNS depressants, and benzodiazepine use without monitoring when misuse risk is high. INDICATION: Seizures (maintenance) · Panic disorder · Anxiety (selected cases).

Primary

  • Seizure disorders (maintenance therapy)
  • Panic disorder

Secondary

  • Selected anxiety disorders (short-term / specialist-guided)

Dosing

STANDARD (ADULT PO)

Adult: start low → titrate slowly; use the lowest effective dose (e.g., 0.25–0.5 mg BID as a common starting range).

ADULT DOSE

STANDARD (ADULT): - Start low (e.g., 0.25–0.5 mg BID) - Titrate gradually based on response and tolerability

PEDIATRIC DOSE

Specialist-based dosing; protocol-based titration and monitoring only.

MAX DOSE

Variable; often up to ~4 mg/day total depending on indication, response, and comorbidities—follow labeling and local protocol.

Practical Note

- Avoid long-term dose escalation; reassess need regularly - Plan taper early if prolonged use is expected - Not a first-line drug for acute seizure termination (rescue regimens are protocol-specific) - Taper on discontinuation—never stop abruptly

Warnings

Clinical warnings

  • Sedation and broad CNS depression
  • Respiratory depression (major risk with opioids and other CNS depressants)
  • Dependence, misuse, and dose escalation with chronic use
  • Cognitive impairment, psychomotor slowing, and fall risk (especially elderly)

Adverse effects

  • Drowsiness
  • Dizziness
  • Ataxia
  • Memory impairment

Contraindications

  • Severe respiratory depression
  • Acute alcohol or CNS depressant intoxication
  • Known hypersensitivity to clonazepam or product components

Drug interactions

  • Opioids: markedly increased risk of respiratory depression, sedation, and death—avoid co-use when possible; lowest doses and close monitoring if unavoidable
  • Alcohol: additive CNS and respiratory depression
  • Other sedative-hypnotics, benzodiazepines, and CNS depressants: increased sedation and respiratory depression

Special populations

Pediatrics

Specialist / protocol-based

Pregnancy

Pregnancy: use only if benefit clearly outweighs fetal risk per obstetric/neurology input (benzodiazepine class effects per labeling).

Lactation

excreted in milk; sedative effects in infant possible—shared decision-making and infant monitoring as appropriate.

Renal impairment

No major renal clearance; use case-by-case monitoring—severe renal impairment: follow product labeling and specialist input.

Hepatic impairment

Hepatic metabolism: use caution; accumulation and prolonged effect possible in significant hepatic impairment—lower starting doses, slower titration, and closer monitoring.

Elderly

Increased sensitivity to sedation, ataxia, and falls; start low, go slow, avoid polypharmacy with other sedatives, and plan falls precautions.

Administration

- Oral dosing - Use the lowest effective dose and shortest duration that meets clinical goals - Avoid abrupt discontinuation—taper with a written plan and follow-up

Monitoring

  • Monitor: - Sedation level and cognition - Respiratory status when opioids, comorbid lung disease, or high-risk co-sedation - Seizure control or anxiety/panic response to therapy
  • Recheck: - After every dose or formulation change (early) and at regular intervals with chronic use - If interacting sedating drugs are started, stopped, or changed
  • Hold / escalate care if: - Excess sedation, confusion, or ataxia - Suspected respiratory depression - Worsening mood, disinhibition, or misuse behaviors

Overdose / toxicity

Clinical Picture

CNS depression, respiratory depression, and coma in severe cases.

Immediate Actions

Support airway, breathing, and circulation; provide ventilatory support as needed; remove/reverse contributing sedatives per toxicology; continuous monitoring in significant ingestion.

Antidote

Flumazenil (benzodiazepine antagonist) may be used in select settings with caution—seizure precipitant in dependent patients; avoid empiric use without resuscitation capability and risk assessment.

Decontamination

Largely supportive—early oral decontamination only when appropriate per toxicology and airway protection.

Escalation

ICU-level monitoring, mechanical ventilation if needed, and specialist toxicology/ICU co-management for refractory CNS/respiratory depression.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Not first-line for acute seizure termination in most settings—rescue is protocol- and site-specific
  • Long half-life / accumulation: reassess need and dose on an ongoing basis

Clinical

  • Always plan a taper and follow-up when used beyond short courses
  • Reassess indication frequently—benzodiazepines are a bridge, not a default chronic plan

Safety

  • Most dangerous everyday pairing: benzodiazepine + opioid—avoid when possible; never leave monitoring assumptions implicit
  • Abrupt stop after chronic use: withdrawal, rebound anxiety, and seizure risk in susceptible patients

Pharmacy Tool

Preparation Calculator

Clonazepam 0.1 mg/mL oral suspension

suspension · oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Hepatic metabolism (cytochrome-mediated pathways; reduced/altered clearance in hepatic impairment) - Long elimination half-life relative to many short-acting benzodiazepines—accumulation with repeated dosing is possible

Mechanism of action

- Potentiates GABA-A receptor–mediated chloride influx → net inhibitory CNS effect (anticonvulsant, anxiolytic, and sedating properties at higher exposure)

Common brand names

Saudi Arabia

Rivotril, Klonopin

Global

Klonopin (example), Rivotril (regional example), Clonazepam (generic)

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Institutional neurology, epilepsy, and psychiatry clonazepam pathways
  • FDA / SFDA product labeling and benzodiazepine boxed warnings (where applicable)
  • Regional controlled-drug and opioid co-prescribing policies